Plain-English translation of NCT06771219 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called for people with advanced cancers that have spread to other parts of the body or stopped responding to previous treatments. Researchers are gradually increasing the dose to find the safest and most effective amount, and the medication is given as an infusion every 3 weeks. This trial includes people with many types of cancer, including breast, lung, ovarian, cervical, thyroid, and others.
Standard cancer treatments don't work for everyone, and some cancers stop responding over time. This trial is exploring whether this medication could offer another option for people whose cancer has progressed despite previous treatment.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an infusion into your vein every 3 weeks, with the dose starting very low and gradually increasing based on how you tolerate it. You'll have regular clinic visits for blood tests, imaging scans (CT or MRI), and possibly a fresh tumor biopsy to help researchers understand how the medication is working. Treatment continues until your cancer progresses or you decide to stop, and the entire trial is expected to enroll about 70 people across different dose levels.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States